196 related articles for article (PubMed ID: 23275831)
21. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
Calò LA; Vertolli U; Pagnin E; Ravarotto V; Davis PA; Lupia M; Naso E; Maiolino G; Naso A
Life Sci; 2016 Mar; 148():80-5. PubMed ID: 26872982
[TBL] [Abstract][Full Text] [Related]
22. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.
Vigil D; Kim TY; Plachco A; Garton AJ; Castaldo L; Pachter JA; Dong H; Chen X; Tokar B; Campbell SL; Der CJ
Cancer Res; 2012 Oct; 72(20):5338-47. PubMed ID: 22942252
[TBL] [Abstract][Full Text] [Related]
23. Expression of Rho Kinase and Its Mechanism in the Left Atrial Appendage in Patients with Atrial Fibrillation.
Chen Y; Su F; Han J; Jiao P; Guo W
Heart Surg Forum; 2018 Feb; 21(1):E044-E048. PubMed ID: 29485964
[TBL] [Abstract][Full Text] [Related]
24. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
[TBL] [Abstract][Full Text] [Related]
25. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
Baraldi PG; Cacciari B; Pineda de Las Infantas MJ; Romagnoli R; Spalluto G; Volpini R; Costanzi S; Vittori S; Cristalli G; Melman N; Park KS; Ji XD; Jacobson KA
J Med Chem; 1998 Aug; 41(17):3174-85. PubMed ID: 9703463
[TBL] [Abstract][Full Text] [Related]
27. Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.
Garton AJ; Castaldo L; Pachter JA
Methods Enzymol; 2008; 439():491-500. PubMed ID: 18374184
[TBL] [Abstract][Full Text] [Related]
28. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
Machado VA; Peixoto D; Costa R; Froufe HJ; Calhelha RC; Abreu RM; Ferreira IC; Soares R; Queiroz MJ
Bioorg Med Chem; 2015 Oct; 23(19):6497-509. PubMed ID: 26344591
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of prostaglandin synthetase by di- and triphenylethylene derivatives: a structure-activity study.
Gilbert J; Miquel JF; Précigoux G; Hospital M; Raynaud JP; Michel F; Crastes de Paulet A
J Med Chem; 1983 May; 26(5):693-9. PubMed ID: 6405034
[TBL] [Abstract][Full Text] [Related]
31. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha).
Ling YZ; Li JS; Liu Y; Kato K; Klus GT; Brodie A
J Med Chem; 1997 Sep; 40(20):3297-304. PubMed ID: 9379450
[TBL] [Abstract][Full Text] [Related]
32. Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase.
Rao SI; Duffel MW
Chirality; 1991; 3(2):104-11. PubMed ID: 1863522
[TBL] [Abstract][Full Text] [Related]
33. Designing of the N-ethyl-4-(pyridin-4-yl)benzamide based potent ROCK1 inhibitors using docking, molecular dynamics, and 3D-QSAR.
Ghosh S; Keretsu S; Cho SJ
PeerJ; 2021; 9():e11951. PubMed ID: 34434664
[TBL] [Abstract][Full Text] [Related]
34. The Design, Structure-Activity, and kinetic studies of 3-Benzyl-5-oxa-1,2,3,4-Tetrahydro-2H-chromeno-(3,4-c)pyridin-8-yl sulfamates as Steroid sulfatase inhibitors.
Chang CN; Lin IC; Lin TS; Chiu PF; Lu YL; Narwane M; Liu IC; Hng Y; Tsai KC; Lin MH; S Y Hsieh Y; Chen MJ; Liang PH
Bioorg Chem; 2022 Dec; 129():106148. PubMed ID: 36244324
[TBL] [Abstract][Full Text] [Related]
35. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
36. Biphenyl urea derivatives as selective CYP1B1 inhibitors.
Mohd Siddique MU; McCann GJ; Sonawane V; Horley N; Williams IS; Joshi P; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Org Biomol Chem; 2016 Sep; 14(38):8931-8936. PubMed ID: 27714268
[TBL] [Abstract][Full Text] [Related]
37. Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
Waldschmidt HV; Homan KT; Cruz-Rodríguez O; Cato MC; Waninger-Saroni J; Larimore KM; Cannavo A; Song J; Cheung JY; Kirchhoff PD; Koch WJ; Tesmer JJ; Larsen SD
J Med Chem; 2016 Apr; 59(8):3793-807. PubMed ID: 27050625
[TBL] [Abstract][Full Text] [Related]
38. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.
Kolhatkar RB; Ghorai SK; George C; Reith ME; Dutta AK
J Med Chem; 2003 May; 46(11):2205-15. PubMed ID: 12747792
[TBL] [Abstract][Full Text] [Related]
39. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
[TBL] [Abstract][Full Text] [Related]
40. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
